Phase II Study of Taletrectinib Shows Clinically Meaningful Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer

The ROS1 tyrosine kinase inhibitor (TKI) taletrectinib demonstrated high overall and intracranial responses, and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC). SAN DIEGO,...